Traduction de «for the commercialization and further » (Néerlandais → Français) :

In October, Novartis signed a collaboration agreement with Cepheid for the commercialization and further development of a test for monitoring of bcr-abl gene transcript.
En octobre, Novartis a signé un accord de collaboration avec Cepheid pour la commercialisation et la poursuite du développement d’un test de surveillance du gène transcrit bcr-abl.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

The commercial paper financing recognizes both attractive funding rates and the strong cash generation of the business, allowing fast repayment of the commercial papers.
Ce type de financement offre l’avantage de présenter des taux intéressants et de tenir compte de la forte génération de trésorerie par le Groupe, ce qui permet de rembourser rapidement ces billets.

Sandoz: USD 1.9 billion (–3%, +4% lc) Key markets achieved solid underlying growth from new product launches and intensified commercialization efforts.
Sandoz: USD 1,9 milliard (-3%, +4% en m. l).

It is often claimed that pharmaceutical companies exercise undue influence on governments and pursue their commercial objectives without taking into consideration society’s interests.
On entend souvent dire que les entreprises pharmaceutiques exercent une influence occulte sur les gouvernements et poursuivent leurs objectifs commerciaux sans tenir compte de l’intérêt du plus grand nombre.

The long-term portion of the Alcon financing was put in place in 2008, 2009 and the first quarter of 2010 (with maturities spanning 3 to 10 years), with the final amount of approximately USD 8.2 billion being financed through an expanded US commercial paper program.
La partie à long terme du financement de l’acquisition d’Alcon a été mise en place en 2008, 2009 et au premier trimestre 2010, assortie de maturités s’échelonnant entre trois et dix ans. Le dernier montant de l’ordre d’USD 8,2 milliards étant financé par un programme étendu de billets de trésorerie aux Etats-Unis.

As of September 30, USD 7.5 billion was outstanding on the US commercial paper program.
Au 30 septembre, ceux-ci ont été ramenés à USD 7,5 milliards.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

Interest expense increased by 26% to USD 496 million from USD 395 million in the prior year period as a result of the issuance of US dollar bonds in February 2009 and March 2010, a Euro bond in June 2009 and the increase of short-term debts through the commercial paper program.
Les charges d’intérêts ont augmenté de 26% à USD 496 millions, en comparaison d'USD 395 millions dans la même période de 2009, à la suite de l’émission d’emprunts obligataires en dollars émis en février 2009 et mars 2010 et d’un emprunt obligataire en euros émis en juin 2009 ainsi que de l’augmentation des dettes à court terme par le biais du programme de billets de trésorerie.